|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.695 GBX | -0.14% |
|
+9.32% | +36.85% |
| 02-06 | Shield Therapeutics plc, 2024 Sales/ Trading Statement Call, Feb 06, 2025 | |
| 02-05 | Shield Therapeutics shares surge as revenue up on prescription growth | AN |
| Capitalization | 28.94M 35.95M 34.74M 32.8M 51.43M 3.12B 57.09M 390M 145M 1.3B 135M 132M 5.47B | P/E ratio 2024 * |
-2.23x | P/E ratio 2025 * | 18.9x |
|---|---|---|---|---|---|
| Enterprise value | 46.44M 57.69M 55.75M 52.63M 82.53M 5.01B 91.62M 627M 233M 2.08B 216M 212M 8.78B | EV / Sales 2024 * |
1.98x | EV / Sales 2025 * | 0.75x |
| Free-Float |
28.41% | Yield 2024 * |
-
| Yield 2025 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Shield Therapeutics plc
More press releases
More news
| 1 day | -0.14% | ||
| 1 week | +9.32% | ||
| Current month | +31.96% | ||
| 1 month | +57.23% | ||
| 3 months | +39.43% | ||
| 6 months | -4.03% | ||
| Current year | +36.85% |
1 week
2.93
3.90
1 month
2.233.90
Current year
2.233.90
1 year
1.065.95
3 years
1.0634.70
5 years
1.06163.00
10 years
1.06202.00
| Director | Title | Age | Since |
|---|---|---|---|
Karl Lundström
CEO | Chief Executive Officer | 63 | 23/07/2024 |
Santosh Shanbhag
DFI | Director of Finance/CFO | 48 | 15/01/2024 |
David Childs
COO | Chief Operating Officer | - | - |
| Manager | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 66 | 31/01/2016 | |
| Chairman | 69 | 17/06/2020 | |
| Director/Board Member | 58 | 25/06/2020 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.14% | +9.32% | -36.84% | -89.08% | 35.95M | ||
| -3.14% | -5.61% | +7.64% | +94.63% | 117B | ||
| -3.61% | -4.53% | -30.20% | +4.24% | 71.22B | ||
| -0.52% | -3.90% | +70.03% | +144.23% | 38.94B | ||
| -0.67% | -2.25% | +22.93% | -33.02% | 27.45B | ||
| +0.71% | -0.76% | +50.51% | +9.37% | 23.61B | ||
| -1.86% | +3.88% | +8.26% | -30.77% | 22.56B | ||
| -6.93% | -7.47% | +324.00% | +800.00% | 14.07B | ||
| +2.27% | -1.38% | +182.80% | +242.29% | 14.29B | ||
| -1.65% | -23.34% | -11.68% | +36.62% | 11.65B | ||
| Average | -0.99% | -0.66% | +58.75% | +117.85% | 34.08B | |
| Weighted average by Cap. | -1.08% | -2.62% | +30.85% | +90.23% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 23.43M 29.11M 28.13M 26.56M 41.64M 2.53B 46.23M 316M 117M 1.05B 109M 107M 4.43B | 63M 78.27M 75.65M 71.41M 112M 6.79B 124M 850M 315M 2.82B 293M 287M 11.92B |
| Net income | -17.91M -22.25M -21.5M -20.3M -31.83M -1.93B -35.33M -242M -89.67M -802M -83.36M -81.71M -3.39B | -6.32M -7.85M -7.59M -7.17M -11.24M -681M -12.47M -85.31M -31.66M -283M -29.43M -28.85M -1.2B |
| Net Debt | 17.5M 21.74M 21.01M 19.84M 31.1M 1.89B 34.53M 236M 87.63M 784M 81.46M 79.85M 3.31B | 18.46M 22.93M 22.17M 20.93M 32.81M 1.99B 36.42M 249M 92.45M 827M 85.94M 84.24M 3.49B |
More financial data
* Estimated data
Employees
73
Calendar
23/04/2025
- Q4 2024 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/02/25 | 3.695 p | -0.14% | 636,460 |
| 11/02/25 | 3.700 p | +5.71% | 8,954,741 |
| 10/02/25 | 3.500 p | +16.67% | 7,026,852 |
| 07/02/25 | 3.000 p | -3.23% | 2,899,580 |
| 06/02/25 | 3.100 p | -8.28% | 2,673,513 |
Delayed Quote London S.E., February 12, 2025 at 09:42 am
More quotes
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.0370GBP
Average target price
0.1675GBP
Spread / Average Target
+352.70%
Annual profits - Rate of surprise
- Stock Market
- Equities
- STX Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition